CA
NZ
UK
AU
IND
US
…
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -78.23M | -79.50M | -73.79M | -120.72M | -75.97M |
| Net income | -79.62M | -77.33M | -73.79M | -117.95M | -81.54M |
| Selling general administrative | 22.19M | 25.42M | 32.61M | 37.35M | 18.66M |
| Selling and marketing expenses | - | - | 1.78M | - | - |
| Gross profit | 11.47M | 15.67M | -2.00M | - | - |
| Reconciled depreciation | 4.51M | 2.98M | 1.43M | 0.71M | 0.65M |
| Ebit | -78.23M | -68.50M | -73.79M | -124.19M | -69.72M |
| Ebitda | -73.72M | -65.51M | -71.86M | -123.48M | -63.49M |
| Depreciation and amortization | 4.51M | 2.98M | 1.93M | 0.71M | 6.23M |
| Non operating income net other | - | - | - | 2.76M | -6.26M |
| Operating income | -84.42M | -89.46M | -82.20M | -123.48M | -69.72M |
| Other operating expenses | 98.28M | 105.61M | 82.20M | 123.48M | 69.72M |
| Interest expense | - | - | - | 2.76M | 6.26M |
| Tax provision | 1.39M | -2.16M | 0.00M | - | - |
| Interest income | 3.61M | 7.04M | 6.91M | 2.76M | 0.02M |
| Net interest income | 3.61M | 7.04M | 6.91M | 2.76M | 0.02M |
| Income tax expense | 1.39M | -2.16M | 1.78M | -2.76M | 5.56M |
| Total revenue | 13.86M | 16.15M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 95.89M | 105.13M | 82.20M | 123.48M | 69.72M |
| Cost of revenue | 2.39M | 0.47M | 2.00M | - | - |
| Total other income expense net | 6.18M | 9.96M | 8.41M | 2.76M | -6.26M |
| Net income from continuing ops | -79.62M | -77.33M | -94.29M | -120.72M | -75.97M |
| Net income applicable to common shares | - | - | - | -120.72M | -75.97M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 91.52M | 157.18M | 173.73M | 211.38M | 280.02M |
| Intangible assets | - | 2.60M | 24.31M | - | - |
| Other current assets | 4.55M | 5.51M | 3.81M | 5.85M | 2.47M |
| Total liab | 38.11M | 36.43M | 48.02M | 50.55M | 18.71M |
| Total stockholder equity | 53.41M | 120.75M | 125.70M | 160.82M | 261.31M |
| Other current liab | 8.55M | 11.37M | 12.97M | 24.54M | 0.27M |
| Common stock | 0.06M | 0.06M | 0.04M | 0.03M | 0.03M |
| Capital stock | 0.06M | 0.06M | 0.04M | 0.03M | 0.03M |
| Retained earnings | -443.18M | -363.56M | -286.23M | -212.44M | -91.72M |
| Other assets | - | - | - | - | 0.11M |
| Cash | 15.42M | 19.47M | 11.14M | 179.29M | 274.74M |
| Total current liabilities | 21.13M | 17.68M | 25.76M | 31.63M | 18.71M |
| Current deferred revenue | - | - | 7.66M | - | 6.33M |
| Net debt | 3.25M | 0.73M | 10.20M | -160.37M | -274.57M |
| Short term debt | 1.69M | 1.45M | 1.23M | - | 0.17M |
| Short long term debt total | 18.67M | 20.20M | 21.33M | 18.92M | 0.17M |
| Other stockholder equity | 496.47M | 484.08M | 411.82M | 373.23M | 353.00M |
| Property plant equipment | - | - | - | 11.16M | 1.01M |
| Total current assets | 72.11M | 132.44M | 124.60M | 186.61M | 278.67M |
| Net tangible assets | - | - | - | 160.82M | 261.31M |
| Short term investments | 51.44M | 107.46M | 109.63M | - | - |
| Net receivables | 0.70M | - | 0.02M | 0.60M | - |
| Inventory | - | - | - | 0.87M | - |
| Accounts payable | 10.88M | 4.86M | 3.90M | 7.10M | 11.95M |
| Accumulated other comprehensive income | 0.05M | 0.17M | 0.06M | - | -280.02M |
| Common stock total equity | - | - | - | 0.03M | 0.03M |
| Retained earnings total equity | - | - | - | -212.44M | -91.72M |
| Non currrent assets other | - | - | - | 13.60M | 0.11M |
| Non current assets total | 19.41M | 24.74M | 49.12M | 24.77M | 1.35M |
| Capital lease obligations | 18.67M | 20.20M | 21.33M | 18.92M | 0.17M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 58.87M | 8.15M | -116.94M | -6.40M | -0.05M |
| Change to liabilities | - | - | - | 3.62M | 9.73M |
| Total cashflows from investing activities | 58.86M | 8.15M | -104.85M | -6.40M | -0.59M |
| Total cash from financing activities | 0.59M | 59.33M | 5.93M | 0.18M | 304.04M |
| Change to operating activities | - | - | - | - | 2.03M |
| Net income | -79.62M | -77.33M | -73.79M | -120.72M | -75.97M |
| Change in cash | -4.05M | 9.81M | -169.63M | -95.55M | 268.13M |
| Begin period cash flow | 20.95M | 11.14M | 180.76M | 276.32M | 8.19M |
| End period cash flow | 16.89M | 20.95M | 11.14M | 180.76M | 276.32M |
| Total cash from operating activities | -63.50M | -57.67M | -70.71M | -89.33M | -35.33M |
| Issuance of capital stock | 0.00M | 59.05M | 6.12M | 0.00M | 303.88M |
| Depreciation | 4.51M | 2.98M | 1.93M | 0.71M | 0.65M |
| Other cashflows from investing activities | 165.87M | 168.51M | - | - | - |
| Sale purchase of stock | - | - | -0.00M | 0.18M | 304.04M |
| Other cashflows from financing activities | -0.15M | 0.28M | -0.19M | -6.40M | 151.75M |
| Change to netincome | - | - | - | 15.76M | 32.67M |
| Capital expenditures | 0.01M | 0.24M | 6.73M | 6.40M | 0.54M |
| Cash flows other operating | - | - | - | 11.29M | -2.40M |
| Cash and cash equivalents changes | - | - | - | -95.55M | 268.13M |
| Change in working capital | 1.94M | -11.82M | -11.66M | 4.50M | 6.68M |
| Stock based compensation | 11.80M | 12.95M | 16.95M | 15.76M | 6.44M |
| Other non cash items | -2.14M | 15.55M | -4.13M | 10.41M | 20.60M |
| Free cash flow | -63.51M | -57.91M | -77.44M | -95.73M | -35.87M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology Inc |
0.07 4.35% |
1.68 | - | - | 25.16 | 25.08 | 24.62 | 1.09 |
| NVO Novo Nordisk A/S |
-0.10 0.24% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.67 0.68% |
538.83 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.89 0.32% |
900.01 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. John L. Flavin M.B.A., MBA, Ph.D. | Co-Founder & Independent Chairman | 1971 |
| Dr. Lara S. Sullivan M.D., MBA | CEO, Pres & Director | NA |
| Ms. Pamela Yanchik Connealy M.B.A. | Chief Financial Officer | 1962 |
| Dr. Jay M. Feingold M.D., Ph.D. | Chief Medical Officer | 1957 |
| Mr. Jitendra Wadhane | Chief Accounting Officer, Sr. VP of Fin. & Corp. Controller | 1980 |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer | NA |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer | NA |
| Ms. Martina Molsbergen B.S. | Interim Chief Bus. Officer | 1965 |
| Dr. Charles T. Gombar Ph.D. | Sr. VP of Portfolio & Program Management | NA |
| Dr. Lara S. Sullivan M.D., MBA | CEO, President & Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.01%
Communication Services
-0.24%
Consumer Cyclical
-0.09%
Consumer Defensive
-0.28%
Energy
+0.34%
Financial Services
-0.26%
Financials
+1.03%
Healthcare
+0.10%
Industrials
+0.23%
Real Estate
-0.26%
Technology
+1.02%
Utilities
-0.00%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...